NCT03730012 2024-11-29
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Completed
Clinical Trials
5 trialsNCT03154827 2024-09-05
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
BioLineRx, Ltd.
Phase 1/2 Terminated
NCT02594384 2024-08-22
LAM-002A/NHL
OrphAI Therapeutics
Phase 1 Completed
NCT04793399 2024-03-19
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Phase 1/2 Terminated
NCT03922477 2022-02-21
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Hoffmann-La Roche
Phase 1 Terminated